| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Acute leukemia is characterized by the abnormal growth of blastic cells in the bone marrow. Leukemia stem cells display relative quiescence, similar to other cancer stem cell populations. Quiescent cells are generally insensitive to conventional anticancer agents. In the present research project, we searched the novel drugs which can eliminate cytokinetically quiescent (G0/G1) leukemia cells. We examined the cytotoxic activity of Bcl-2 inhibitor Venetoclax and Mcl-1 inhibitor S63845 against leukemia cells including cytokinetically quiescent (G0/G1) cells. Both Venetoclax and S63845 efficiently killed the quiescent leukemia cells via inhibition of Bcl-2 and Mcl-1 protein function. We observed synergistic killing action on leukemia cells when these drugs were simultaneously used as combination therapy. These unique features of these drugs may be beneficial for the development of new therapeutic strategies to eliminate quiescent leukemia cells.
|
